Kansas Clinical Trials

A listing of Kansas clinical trials actively recruiting patient volunteers.

Sharing its biggest city of Kansas City with its neighbors in Missouri, Kansas is the iconic prairie state and childhood home of Superman. Topeka, Wichita, and Overland Park are some of the other cities, with Overland Park serving as a hub for technology businesses. Kansas has long been one of the most important agricultural centers of the nation, producing more wheat than any other state. These days, it also contributes to aerospace research through an astonishing number of local companies. Healthcare has been growing rapidly in Kansas, with University of Kansas Hospital leading the way as the state's largest provider.

Search by Name
Search
Filter by Condition
1033 trials found

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus-Like Particle Vaccine

NCT05065983

The objective of this study is to assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus-Like Particle Vaccine [CHIKV VLP], alum-adjuvanted).

Conditions: Chikungunya Virus

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

NCT05066230

This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Conditions: Non-proliferative Diabetic Retinopathy

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

NCT05067933

Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19. Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-do ...

Conditions: COVID-19

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546

The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.

Conditions: Respiratory Syncytial Virus Infection Prevention

Heat Shock Therapy to Improve Mitochondrial Function in Neuropathy

NCT05070741

Sensory dysfunction as a result of peripheral nerve damage is a significant problem that leads to reduced quality of life for patients. The prevalence of sensory dysfunction in peripheral neuropathy associates with epidemic increases in prediabetes and diabetes, but also is relevant to chemotherapy treatments and genetic disorders. Clinical approaches to treat peripheral neuropathy and to stimulate axon growth in settings of peripheral axon loss are limited. Although new drugs will hopefully be ...

Conditions: PreDiabetes, Neuropathy
Phase: Not Applicable

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

NCT05072080

The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 in healthy adult and adolescent subjects.

Conditions: Chikungunya Virus

Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection

NCT05075850

PatiEnt Neuropsychological outcomeS After laseR ablation

Conditions: Cognitive Change

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

NCT05081167

This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.

Conditions: Major Depressive Disorder

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

NCT05085366

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants.

Conditions: Cytomegalovirus Infection

The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects

NCT05085197

This was a single ascending dose, randomized, double-blind study assessing the safety, tolerability and pharmacokinetics of STSA-1005 in healthy participants. Four kinds different doses and dose-matched placebo were administered under fasted conditions.

Conditions: Healthy

Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC

NCT05094544

The current proposal is structured as a pilot trial to evaluate the impact of non-ablative SBRT (800 cGy X 3 fractions) as an immunomodulatory mechanism in patients with early stage NSCLC who are surgical candidates. Tumor, normal tissue and blood specimens will be analyzed for immunomodulatory changes including phenotypic changes in tumor cell surface marker expression, tumor and normal tissue microenvironment and gene expression profiles, serum/blood immune profile changes, and circulating tum ...

Conditions: Non-small Cell Lung Cancer
Phase: Not Applicable

A Pharmacokinetic Study of TP-05 in Healthy Subjects

NCT05138796

A Phase 1, Randomized, Double-Blind, Single- and Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Food-Effect and Pharmacokinetics of TP-05 in Healthy Subjects

Conditions: Healthy